Key Takeaways
- AbbVie is funding its planned Apogee Therapeutics acquisition with debt, and CFO Scott Reents raised full-year net interest expense guidance by $200 million to roughly $2.9 billion because of it.
- AbbVie’s quarterly dividend sits at $1.73, up from $1.64 a year earlier.
- At 84.97% of trailing earnings, AbbVie stock’s payout ratio dwarfs its 2.74% dividend yield, the lowest reading in its own two-year range.
- TIKR’s mid case model prices AbbVie stock at a $361 target by the end of 2030, worth a 37% total return and an 8% annualized rate from today’s $263.
AbbVie Stock Faces Rising Financing Costs Just as Guidance Climbs
AbbVie (ABBV) closed the books on the second quarter of 2026 with adjusted earnings per share of $3.65, six cents above its own guidance midpoint. Chairman and CEO Rob Michael called it “another excellent quarter,” but the number carried a $0.17 hit from acquired IPR&D expense tied to the company’s deal-making.
That total net revenue came in at nearly $17 billion, up 10% and $300 million ahead of expectations. Skyrizi and Rinvoq, AbbVie’s two largest immunology drugs, each grew sales more than 20%, per Chief Commercial Officer Jeff Stewart.
Scott Reents, the CFO, raised full-year revenue guidance to roughly $67.6 billion, an increase of $300 million that brings the total guidance raise this year to $600 million. That guidance also folds in the pending purchase of Apogee Therapeutics, a deal Reents said adds $0.14 of per-share dilution this year, more than offsetting a $0.10 improvement in the underlying business.
Reents also raised full-year net interest expense guidance by $200 million to about $2.9 billion, reflecting the partial-year financing cost of the acquisition. “We remain committed to achieving a net leverage ratio of two times within two to three years following the deal close,” Reents told analysts.
Michael separately called the company’s financial capacity for more business development ample, even as AbbVie finances Apogee with interim debt and plans to issue long-term bonds in the coming months. None of that commentary named the dividend directly, but every guidance line management touched this quarter narrows the room a debt-financed acquisition leaves for shareholder returns.
AbbVie Stock’s Dividend Keeps Rising Even as Its Yield Hits a Two-Year Low
AbbVie’s quarterly dividend has climbed twice inside the two years of data TIKR provides, moving from $1.55 to $1.64 and then to $1.73, where it has held for three straight quarters. That pattern reads as a board still committed to steady increases rather than one pausing to conserve cash for the Apogee deal.
The payout ratio tells a messier story. AbbVie’s payout ratio has swung from a loss-making -12,509.09% in the fourth quarter of 2024 to a peak of 1,565.05% in the third quarter of 2025, before settling at 84.97% in the most recent quarter. Those swings point to volatile GAAP earnings, not volatile cash generation, the same kind of episodic charge that shaved $0.17 off this quarter’s adjusted EPS from acquired IPR&D expense. Even excluding the extremes, a payout ratio parked at 84.97% still leaves less room to raise the dividend further without earnings growth doing the heavy lifting.
AbbVie stock’s dividend yield closed most recently at 2.74%, just above the 2.65% floor of its own trailing range and well under the 3.41% average. That leaves income buyers paying a much richer price for the same dollar of dividend than they would have gotten across most of the past two years.
Bulls can point to two dividend increases and a quarterly payment that has never moved backward. Bears can point to a 2.74% yield sitting far closer to the range’s 2.65% floor than its 4.49% high, struck within the same two years.
TIKR’s $361 Target Says AbbVie Stock Still Has Room to Run
TIKR’s mid case model prices AbbVie stock at a $361 target by the end of 2030, a 37% total return and an 8% annualized rate from today’s $263 share price.
That path treats AbbVie stock as a total-return story, where price appreciation carries most of the gain and the dividend layers on top of it rather than driving it.
The case for reaching that target leans on the same growth management flagged on the call: revenue guided to roughly $67.6 billion this year and Skyrizi and Rinvoq each growing sales more than 20%. Apogee adds near-term financing costs, but it also expands the immunology pipeline the model is pricing in past 2030.
Should You Invest in AbbVie Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AbbVie Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ABBV stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
